e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
106.45
+1.19 (+1.13%)
Official Closing Price
Updated: 7:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
99
100
Next >
PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
February 04, 2025
Via
Benzinga
Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock Drops
February 04, 2025
Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.8% year on year to $15.62 billion. On the other hand, the company’s...
Via
StockStory
Merck Tops Q4 Forecasts, But Dow Jones Giant Dives On 2025 Guidance
↗
February 04, 2025
Merck topped Wall Street's Q4 expectations Tuesday, but the stock is taking a hit on light guidance.
Via
Investor's Business Daily
Topics
Stocks
Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
February 04, 2025
From
Merck & Co., Inc.
Via
Business Wire
Market Whales and Their Recent Bets on MRK Options
↗
January 31, 2025
Via
Benzinga
A Closer Look at Merck & Co's Options Market Dynamics
↗
January 29, 2025
Via
Benzinga
Forecasting The Future: 12 Analyst Projections For Merck & Co
↗
January 28, 2025
Via
Benzinga
Balancing Dividends and Fundamentals: The Case of NYSE:MRK.
↗
January 28, 2025
Exploring MERCK & CO. INC. (NYSE:MRK)'s dividend characteristics.
Via
Chartmill
Earnings Scheduled For February 4, 2025
↗
February 04, 2025
Via
Benzinga
Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings?
↗
February 03, 2025
Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which stock will prevail. While Merck shows short-term strength, Pfizer is...
Via
Benzinga
The Dogs Of The Dow 2025
↗
January 31, 2025
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors.
Via
Talk Markets
Topics
Stocks
Stocks / Equities
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
↗
January 31, 2025
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.
Via
Benzinga
5 Top Stocks to Buy in February 2025
↗
January 31, 2025
All of them have great upside.
Via
The Motley Fool
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
January 31, 2025
From
Merck & Co., Inc.
Via
Business Wire
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond
↗
January 27, 2025
Via
The Motley Fool
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
↗
January 23, 2025
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals.
Via
Chartmill
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
January 30, 2025
From
Merck & Co., Inc.
Via
Business Wire
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
↗
January 29, 2025
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
Via
Benzinga
Topics
Government
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
↗
January 29, 2025
The Senate will meet Wednesday to start the confirmation hearing process for Robert F. Kennedy Jr.
Via
Investor's Business Daily
Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
January 28, 2025
From
Merck & Co., Inc.
Via
Business Wire
FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)
January 27, 2025
From
Merck & Co., Inc.
Via
Business Wire
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
↗
January 25, 2025
Via
The Motley Fool
Topics
Stocks
Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study
↗
January 24, 2025
Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.
Via
Benzinga
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
↗
January 24, 2025
Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.
Via
Investor's Business Daily
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
January 24, 2025
From
Merck & Co., Inc.
Via
Business Wire
RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing
↗
January 23, 2025
Robert F. Kennedy Jr., HHS secretary nominee, faces criticism for financial ties to vaccine lawsuits, raising ethical concerns over regulatory impartiality.
Via
Benzinga
Topics
Lawsuit
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
↗
January 23, 2025
Via
The Motley Fool
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
↗
January 22, 2025
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.
Via
Benzinga
Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines
↗
January 22, 2025
Ellison, Oracle's chairman, pointed to the use of AI to develop drugs like Moderna's cancer vaccine.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Why Summit Therapeutics Stock Is Jumping Today
↗
January 21, 2025
Via
The Motley Fool
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.